Axsome Therapeutics Inc (GB:0HKF)

Axsome Therapeutics (0HKF) Stock Price & Analysis


0HKF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$22.05 - $82.45
Previous Close$69.98
Average Volume (3M)563.00
Market Cap
Enterprise Value$2.94B
Total Cash (Recent Filing)$246.51M
Total Debt (Recent Filing)$147.72M
Price to Earnings (P/E)N/A
Aug 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding43,573,213
10 Day Avg. Volume117
30 Day Avg. Volume563
Standard Deviation0.46
Financial Highlights & Ratios
Price to Book (P/B)101.22
Price to Sales (P/S)31.95
Price to Cash Flow (P/CF)-27.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.35
Enterprise Value/Gross Profit62.96
Enterprise Value/Ebitda-21.59
Price Target Upside50.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8




What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $22.05 and its highest was $82.44 in the past 12 months.
    What is Axsome Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Axsome Therapeutics Inc’s upcoming earnings report date?
    Axsome Therapeutics Inc’s upcoming earnings report date is Aug 09, 2023 which is in 73 days.
      How were Axsome Therapeutics Inc’s earnings last quarter?
      Axsome Therapeutics Inc released its earnings results on May 08, 2023. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$1.304 by $1.044.
        Is Axsome Therapeutics Inc overvalued?
        According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Axsome Therapeutics Inc pay dividends?
          Axsome Therapeutics Inc does not currently pay dividends.
          What is Axsome Therapeutics Inc’s EPS estimate?
          Axsome Therapeutics Inc’s EPS estimate is -$1.27.
            How many shares outstanding does Axsome Therapeutics Inc have?
            Currently, no data Available
            What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
            Axsome Therapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$1.304. Following the earnings report the stock price went up 5.194%.
              Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
              Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 124M.


                Axsome Therapeutics Stock Smart Score

                The Axsome Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Axsome Therapeutics Inc

                Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Elanco Animal Health
                Intra-Cellular Therapies
                Axsome Therapeutics
                Prestige Consumer Healthcare
                Harmony Biosciences Holdings

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis